William Blair analyst Brandon Vazquez upgraded Medtronic (MDT) to Outperform from Market Perform without a price target as part of its 2026 outlook for the medical technology group. The company has several new and ramping launches this year, the analyst tells investors in a research note. William Blair says volumes and spending budgets “remain solid” in the medtech space with earnings estimates “finally going up.” This is a good setup for medtech into 2026, contends the firm.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic: Fairly Valued on Aligned EPS Guidance and Higher Interest Costs, Justifying a Hold Rating
- Medtronic put volume heavy and directionally bearish
- The Week That Was, The Week Ahead: Macro & Markets, Dec. 20
- Medtronic announces filing of IPO registration for MiniMed
- Medtronic price target lowered to $107 from $110 at Truist